Humanigen Inc (HGENQ)

[cowtown jay]

If I had designed the ACTIV-5 trial, I wouldn't want to publish the trial data, either. This goes beyond the run-of-the-mill graft. Lenz could have saved millions of lives that were lost as a result of this sacrifice before the altar of legacy vaccinations. There could, and should, be repercussions for keeping lenz off the market, and allowing these preventable deaths to occur.

Still, the fact that patients in ordinal scales 6 and 7 were included in ACTIV-5, will provide some data from these late-stage patients that LIVE-AIR did not and never intended to treat. We can compare those data to Gohibic, which recently got an EUA for treatment of those late-stage patients.

https://www.inflarx.de/Home/Investors/Press-Releases/04-2023-InflaRx-Receives-FDA-Emergency-Use-Authorization-for--Gohibic--vilobelimab--for-Treatment-of-Critically-Ill-COVID-19-Patients-.html

Further detail on the patient you mention are provided in the case report.

https://osf.io/xusr9/